このエントリーをはてなブックマークに追加
ID 49387
FullText URL
Thumnail 125_57.pdf 1.04 MB
Title Alternative
Lung cancer and molecular targeted drugs
Author
Keywords
肺癌
分子プロファイリング
分子標的薬
EGFR遺伝子変異
ALK融合遺伝子
Note
特集 分子標的治療 (Molecularly targeted therapy)
Published Date
2013-04-01
Publication Title
岡山医学会雑誌
Publication Title Alternative
Journal of Okayama Medical Association
Volume
volume125
Issue
issue1
Publisher
岡山医学会
Publisher Alternative
Okayama Medical Association
Start Page
57
End Page
66
ISSN
0030-1558
NCID
AN00032489
Content Type
Journal Article
Related Url
http://www.okayama-u.ac.jp/user/oma/
References
1) Global Health Observatory. Cause of death 2008 by World Health Organization. http://www.who.int/gho/mortality_burden_disease/causes_death_2008/en/index.html(2013年1月閲覧)
2) 人口動態統計(厚生労働省大臣官房統計情報部編), 地域がん登録全国推計値 国立がんセンターがん対策情報センター. http://ganjoho.ncc.go.jp/professional/statistics/index.html(2011年10月閲覧)
3) Molecular Profiling of Lung Cancer. My Cancer Genome by the Vanderbilt-Ingram Cancer Center. http://www.mycancergenome.org/content/other/molecular-pathology/targeted-therapeutics(2013年1月閲覧)
4) Non-small cell lung cancer, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) version 1.2013. http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf(2013年1月閲覧)
5) Kozuki T, Kiura K, Ueoka H, Tabata M, Date H, Hamazaki S, Bessho A, Tanimoto M : Long-term effect of gefitinib (ZD1839) on squamous cell carcinoma of the lung. Anticancer Res (2004) 24, 393-396.
6) Zhang D, Takigawa N, Ochi N, Tanimoto Y, Noujima D, Chen YY, Tanimoto M, Kiura K : Detection of the EGFR mutation in exhaled breath condensate from a heavy smoker with squamous cell carcinoma of the lung. Lung Cancer (2011) 73, 379-380.
7) Hata A, Katakami N, Yoshioka H, Kunimasa K, Fujita S, Kaji R, Notohara K, Imai Y, Tachikawa R, Tomii K, Korogi Y, Iwasaku M, et al. : How sensitive are epidermal growth factor receptor tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations? J Thorac Oncol (2013) 8, 89-95.
8) Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH : Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 355, 2542-2550.
9) Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, et al. : Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol (2008) 26, 3543-3551.
10) Lung Cancer Mutation Consortium. http://www.golcmc.com/(2013年1月閲覧)
11) Bleeker FE, Felicioni L, Buttitta F, Lamba S, Cardone L, Rodolfo M, Scarpa A, Leenstra S, Frattini M, Barbareschi M, Grammastro MD, Sciarrotta MG, et al. : AKT1 (E17K) in human solid tumours. Oncogene (2008) 27, 5648-5650.
12) 光冨徹哉, 谷田部 恭, 秋田弘俊, 弦間昭彦, 曽田 学, 豊岡伸一, 中川和彦, 西尾和人, 萩原 一 : 肺癌患者におけるALK遺伝子検査の手引き, 日本肺癌学会バイオマーカー委員会. http://www.haigan.gr.jp/uploads/photos/366.pdf(2012年9月閲覧)
13) Center for drug evaluation and research application. Number : 202570Orig1s000 Cross discipline team leader review. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202570Orig1s000CrossR.pdf(2013年1月閲覧)
14) Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, Nardone J, Lee K, Reeves C, Li Y, Hu Y, Tan Z, et al. : Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell (2007) 131, 1190-1203.
15) Takeuchi K, Choi YL, Togashi Y, Soda M, Hatano S, Inamura K, Takada S, Ueno T, Yamashita Y, Satoh Y, Okumura S, Nakagawa K, et al. : KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res (2009) 15, 3143-3149.
16) Togashi Y, Soda M, Sakata S, Sugawara E, Hatano S, Asaka R, Nakajima T, Mano H, Takeuchi K : KLC1-ALK : a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS One (2012) 7, e31323.
17) Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, Salgia R, Fidias P, et al. : Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer : updated results from a phase 1 study. Lancet Oncol (2012) 13, 1011-1019.
18) Sakamoto H, Tsukaguchi T, Hiroshima S, Kodama T, Kobayashi T, Fukami TA, Oikawa N, Tsukuda T, Ishii N, Aoki Y : CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell (2011) 19, 679-690.
19) Sequist LV, Gettinger S, Senzer NN, Martins RG, Jänne PA, Lilenbaum R, Gray JE, Iafrate AJ, Katayama R, Hafeez N, Sweeney J, Walker JR, et al. : Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol (2010) 28, 4953-4960.
20) Gautschi O, Pauli C, Strobel K, Hirschmann A, Printzen G, Aebi S, Diebold J : A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J Thorac Oncol (2012) 7, e23-24.
21) Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, Brace LE, Woods BA, Lin W, Zhang J, Deng X, Lim SM, et al. : Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov (2011) 1, 78-89.
22) Herbst RS, Fukuoka M, Baselga J : Gefitinib--a novel targeted approach to treating cancer. Nat Rev Cancer (2004) 4, 956-965.
23) Fujiwara K, Kiura K, Ueoka H, Tabata M, Hamasaki S, Tanimoto M : Dramatic effect of ZD1839 (‘Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status. Lung Cancer (2003) 40, 73-76.
24) Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, et al. : Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol (2003) 21, 2237-2246.
25) Kiura K, Takigawa N, Segawa Y : Advanced non-small cell lung carcinoma acquired resistance to gefitinib ; in Methods of Cancer Diagnosis, Therapy and Prognosis : General Methods and Overviews, Lung Carcinoma and Prostate Carcinoma, Hayat, M.A.(ed), Springer, Netherlands (2008) pp307-317.
26) Suda K, Mizuuchi H, Maehara Y, Mitsudomi T : Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny. Cancer Metastasis Rev (2012) 31, 807-814.
27) Hirsch FR, Bunn PA Jr : A new generation of EGFR tyrosine-kinase inhibitors in NSCLC. Lancet Oncol (2012) 13, 442-443.
28) Brzezniak C, Carter CA, Giaccone G : Dacomitinib, a new therapy for the treatment of non-small cell lung cancer. Expert Opin Pharmacother (2013) 14, 247-253.
29) Dutt A, Ramos AH, Hammerman PS, Mermel C, Cho J, Sharifnia T, Chande A, Tanaka KE, Stransky N, Greulich H, Gray NS, Meyerson M : Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One (2011) 6, e20351.
30) Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soitermann A, Moch H, Wagencr P, et al. : Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med (2010) 2, 62ra93.
31) De Grève J, Teugels E, Geers C, Decoster L, Galdermans D, De Mey J, Everaert H, Umelo I, In't Veld P, Schallier D : Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer (2012) 76, 123-127.
32) Marks JL, Gong Y, Chitale D, Golas B, McLellan MD, Kasai Y, Ding L, Mardis ER, Wilson RK, Solit D, Levine R, Michel K, et al. : Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res (2008) 68, 5524-5528.
33) Ou SH, Kwak EL, Siwak-Tapp C, Dy J, Bergethon K, Clark JW, Camidge DR, Solomon BJ, Maki PG, Bang YJ, Kim DW, Christensen J, et al. : Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol (2011) 6, 942-946.
34) Kawano O, Sasaki H, Endo K, Suzuki E, Haneda H, Yukiue H, Kobayashi Y, Yano M, Fujii Y : PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer (2006) 54, 209-215.
35) Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, Akhavanfard S, Heist RS, et al. : Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med (2011) 3, 75ra26.
36) Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, Demanse D, De Buck SS, Ru QC, Peters M, Goldbrunner M, Baselga J : Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol (2012) 30, 282-290.
37) Zou ZQ, Zhang XH, Wang F, Shen QJ, Xu J, Zhang LN,Xing WH, Zhuo RJ, Li D : A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells. Int J Mol Med (2009) 24, 97-101.
38) Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, Chirieace LR, Kaur R, et al. : Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med (2008) 14, 1351-1356.
39) Birchmeier C, Sharma S, Wigler M : Expression and rearrangement of the ROS1 gene in human glioblastoma cells. Proc Natl Acad Sci U S A (1987) 84, 9270-9274.
40) Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Hark EJ, Batten JM, et al. : ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol (2012) 30, 863-870.
41) Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, Nardone J, Lee K, Reeves C, Li Y, Hu Y, Tan Z, et al. : Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell (2007) 131, 1190-1203.
language
日本語
Copyright Holders
Copyright (c) 2013 岡山医学会
File Version
publisher
Refereed
True
DOI
Eprints Journal Name
joma